

# Index

- A**
- A-192558, 721
  - A-315675, 721
  - ACM. *See* Antigen clearance model
  - Acute respiratory distress syndrome (ARDS), 249, 552
  - Aging
    - CD8 T-cell response, 566–567
    - influenza susceptibility and severity, 248–250, 285–287
  - Amantadine, H7N9 resistance, 375
  - ANP32, 7–8, 123–126
  - ANT3, 555
  - Antigen clearance model (ACM), 586–589
  - Antigenic distance hypothesis, 652
  - Antigenic drift, evolution, 211, 213
  - Antiviral therapy. *See also specific drugs*
    - antibodies, 690–695, 725–727
    - combination therapy, 695–696
    - hemagglutinin inhibitors, 688–690
    - host-directed therapies, 696–697
    - neuraminidase inhibitors, 685–688, 717–728
    - overview, 679–680
    - polymerase inhibitors, 680–684, 707–713
    - prospects, 700–701
    - study design for hospitalized influenza patients
      - end points, 697–699
      - populations, 699
      - type of study, 700
  - AP-1, 145, 553, 617
  - ARDS. *See* Acute respiratory distress syndrome
  - Aspirin, NF- $\kappa$ B inhibition, 142
  - Asthma, influenza susceptibility and severity, 287–288
  - ATF-2, 140, 145
  - Avian influenza viruses. *See also specific viruses*
    - clinical manifestations of human infection, 321–322
    - epidemiology of human infection
      - H5N1, 314, 317
      - H5N6, 315
      - H7N7, 315
      - H7N9, 315, 317
      - H7N4, 315
      - H9N2, 315
      - H10N7, 317
      - H10N8, 317
    - evolution
      - H5N6, 321
      - H7N9
        - high-pathogenicity viruses, 319, 321
        - low-pathogenicity viruses, 319
      - emerging viruses, 334–336
    - H5N1 in Egypt. *See* H5N1
    - H7N9 in China. *See* H7N9
    - high-pathogenicity viruses
      - documented outbreaks, epidemics, and pandemics, 421–426
      - emergence mechanisms, 420, 427–428
      - genetic lineages associated with outbreaks, 428–435
      - historical perspective, 419–420
      - prospects for study, 435–436
    - molecular markers of human pathogens, 318–320
    - overview, 313–314
    - prospects for study, 324
    - reassortment, 207–208, 359
    - receptor-binding profiles of human pathogens, 317–318
    - severe infection
      - cytokine storm, 323
      - susceptibility
        - host factors, 323–324
        - viral factors, 322–323
    - spillover into dogs and cats, 488–489
    - tissue tropism, 323–324
- B**
- Baloxavir acid (BXA), 20
  - Baloxavir marboxil
    - efficacy, 681–682, 712
    - mechanism of action, 711
    - overview, 680–681, 710–711
    - resistance, 682, 712
    - safety, 682
  - Bat influenza A viruses
    - evolution, 498–500
    - H18N11

## Index

- Bat influenza A viruses (*Continued*)  
    replication efficiency, 503–504  
    replication without N11, 501–502  
    zoonotic risk, 505–506  
    hemagglutinin and MHC class II molecules,  
        500–501  
    NA protein counteracting HA function, 502–503  
    overview, 497–498  
    prospects for study, 506
- B cell  
    immunization response. *See* Vaccination  
    influenza immune response, 561–564  
    recall antibody studies after infection  
        animal models, 531–532  
        humans, 529–530, 583–584
- BiFC. *See* Bimolecular fluorescent  
    complementation
- Bimolecular fluorescent complementation  
    (BiFC), 165–166
- BXA. *See* Baloxavir acid
- C**
- Canine influenza viruses  
    avian influenza virus spillover, 488–489  
    H3N2, 485–487  
    H3N8, 484–485  
    human influenza virus spillover, 487–488  
    overview, 483  
    pathogenesis, 487
- CCL4, 552
- CD25, 268
- CD55, 255, 324
- CF. *See* Cystic fibrosis
- cGAS, 599
- Children. *See* Pediatric influenza
- Chronic obstructive pulmonary disease  
    (COPD), 252, 288
- CLIP-Seq, 167–168
- CLUH, nuclear export role, 130
- CMTR1, cap snatching role, 120
- CMV. *See* Cytomegalovirus
- COPD. *See* Chronic obstructive pulmonary disease
- CPSF30, 553
- CR6261  
    efficacy, 693  
    mechanism of action, 693
- CR8020  
    efficacy, 693–694  
    mechanism of action, 693
- CRISPR–Cas9, 124, 127, 156, 161–163
- CRM1, nuclear export role, 129–130, 144
- CRTAM, 558
- CT-P27  
    efficacy, 694  
    mechanism of action, 693
- CXCL10, 552
- Cystic fibrosis (CF), influenza susceptibility  
    and severity, 288–289
- Cytomegalovirus (CMV), 249–250
- D**
- DDX3, 555
- Deep mutational scanning (DMS), 168
- Defective interfering RNA, 8–9
- Defective ribosome products (DRiPs), influenza A  
    virus function, 92
- Defective virus genome (DVG), transmission,  
    187–189
- DFSAs, 721
- DHA. *See* Docosahexaenoic acid
- Diabetes, influenza susceptibility and severity,  
    251, 288
- Diridavumab. *See* CR6261
- DMS. *See* Deep mutational scanning
- Docosahexaenoic acid (DHA), 281
- DRiPs. *See* Defective ribosome products
- DVG. *See* Defective virus genome
- E**
- E1B-AP5, 554
- EEA1, 145–146
- EMM. *See* Epitope masking model
- Epidemiology, human influenza  
    avian influenza viruses  
        H5N1, 314, 317  
        H5N6, 315  
        H7N4, 315  
        H7N7, 315  
        H7N9, 315, 317  
        H9N2, 315  
        H10N7, 317  
        H10N8, 317  
    control  
        antiviral drugs, 307  
        nonpharmaceutical interventions, 307–309  
        vaccination, 306–307  
    equine influenza viruses, 474–475  
    incidence, 302–304  
    public health impact, 305–306  
    seasonality, 302  
    severity profile, 304–305  
    transmission modeling, 301–302
- Epitope masking model (EMM), 587–589

- Equine influenza viruses
  - clinical features in horses, 472–474
  - epidemiology, 474–475
  - evolution and antigenic drift, 468–471
  - historical perspective, 466–468
  - overview, 465–466
  - transmission between species, 471–472
  - vaccination, 475–476
- Estradiol, 283
- Evolution, influenza viruses
  - antigenic drift, 211, 213
  - avian influenza viruses
    - H5N6, 321
    - H7N9
      - high-pathogenicity viruses, 319, 321
      - low-pathogenicity viruses, 319
  - bat influenza A viruses, 498–500
  - cross-species transmission and evolution, 205–207
  - equine influenza viruses, 468–471
  - genetic reassortment
    - avian influenza A virus, 207–208
    - human influenza viruses, 208, 210
    - overview, 207
    - swine influenza viruses, 208
  - H5N1 in Egypt, 355–358
  - H7N9 in China, 368–370
  - intra-host evolution, 213–214
  - metagenomic studies, 202–204
  - molecular epidemiology, 210–213
  - origins, 201–202
  - phylogenetic patterns, 210–212
  - swine influenza A virus sustained lineages
    - 1A, 445
    - 1B, 445–446
    - 1C, 446
    - H3, 446–447
  - timescale, 204–205
- F
- Favipiravir
  - efficacy, 684, 708–709
  - mechanism of action, 708
  - overview, 683–684, 708
  - resistance, 684, 709
  - safety, 684
- Fc receptor-mediated inhibition model (FIM), 587–589
- Feline influenza viruses
  - avian influenza virus spillover, 488–489
  - human influenza virus spillover, 487–488
  - overview, 483
- Ferret model
  - overview, 511–512
  - pathogenicity, 518–519
  - pathogenicity of influenza virus, 513–515
  - prospects for study, 519–521
  - transmission of influenza virus, 515–517
- FIM. *See* Fc receptor-mediated inhibition model
- FluPol. *See* RNA polymerase, influenza virus
- FOXP3, 268
- G
- Gene correlation analysis, influenza host factor identification, 163
- Genome, influenza virus
  - influenza A virus
    - packaging
      - models, 103
      - prospects for study, 107–108
      - ribonucleoprotein organization within virion, 103–105
      - RNA–RNA interactions, 105–107
      - segment-specific packaging, 102–103
      - structure, 2, 79–80, 100–102
    - replication
      - host factors
        - ANP32, 123–126
        - Hsp90, 121–122
        - MCM, 121
        - nonprotein host factors, 126–127
        - UAP56, 121–123
      - overview, 120–121
      - RNA polymerase, influenza virus, 6–7
- GOT2, 126
- Gut microbiota
  - animal studies of influenza transmission, 194–195
  - disruption and influenza infection risk, 252
- H
- H1N1
  - live attenuated influenza vaccine effectiveness, 665–668
  - pandemics, 334. *See also* Spanish influenza pandemic
  - reassortment, 210
  - transmission, 186, 189–190, 193
  - vaccine effectiveness, 650
- H2N2
  - B-cell immune response, 563
  - evolution, 446–447
  - pandemic, 230–231, 332, 334
  - reassortment, 208
  - transmission, 186–187, 189–190, 193–194, 207

## Index

- H3N2, vaccine effectiveness, 650–651
- H3N8
  - cross-species transmission, 207
  - transmission of equine virus, 471–472
- H5N1
  - antigenic drift, 213
  - Egypt
    - biological properties, 358
    - control
      - active surveillance, 361
      - biosecurity enhancement, 359–361
      - culling of infected poultry, 361
      - vaccination, 360
    - emergence, 354
    - epidemiology, 354–355
    - evolution, 355–358
    - overview, 353–354
    - prospects for study, 362
    - reassortment, 359
    - zoonotic infections, 358–359
  - epidemiology, 314, 317
  - reassortment, 208
  - spillover into dogs and cats, 488–489
  - transmission, 189–190
- H5N6
  - epidemiology, 315
  - evolution, 321
- H5N8, emergence in Egypt, 359
- H7N2, cat outbreak, 489–490
- H7N4, epidemiology, 315
- H7N7
  - epidemiology, 315
  - transmission, 194
- H7N9
  - antigenic drift, 213
  - China
    - adaptation, 370
    - antigenicity, 375–376
    - control, 376–377
    - drug resistance, 375
    - emergence and evolution, 368–370
    - hemagglutinin receptor binding, 372–374
    - overview, 367–368
    - pathogenesis, 370–372
    - prospects for study, 377
    - transmission, 374–375
  - epidemiology, 315, 317
  - evolution
    - high-pathogenicity viruses, 319, 321
    - low-pathogenicity viruses, 319
  - reassortment, 208
  - transmission, 189
- H9N2
  - antigenic sites, 404–406
  - clinical features, 395
  - epidemiology, 315
  - hemagglutinin features, 403, 407
  - lineage
    - Americas, 387, 389, 393
    - Eurasian lineage, 393–395
    - overview, 387, 390–392
  - natural history, 385, 387
  - origins, 202
  - overview, 385
  - pathology, 395–396
  - prospects for study, 407–408
  - public health risks, 395
  - reassortment, 208
  - transmission, 396–397, 403
  - tropism determinants, 398–400
  - vaccination, 407
  - virulence determinants, 401–402
- H9N3, species distribution, 386
- H9N4, species distribution, 386
- H9N5, species distribution, 386
- H9N6, species distribution, 386
- H9N7, species distribution, 386
- H9N8, species distribution, 386
- H10N7, 317
- H10N8, 317
- H17N10, 202, 407
- H18N11
  - control, 407
  - origins, 202
  - replication, 501–504
  - zoonotic risk, 505–506
- HA. *See* Hemagglutinin
- Hemagglutinin (HA)
  - antibodies
    - broadly reactive antibodies, 62–64
    - hemagglutinin receptor-binding site, 61–62
    - stem domain, 59–61
  - antigenic drift, 211, 582
  - antigenicity, 46–47, 58–59
  - avian influenza virus features in human infection, 318–319
  - B-cell antigens, 561
  - bat influenza A viruses MHC class II molecules, 500–501
  - classification, 53, 113–114
  - H5N1 prime and boost vaccination antibody responses, 590
  - H7N9 receptor binding, 372–374
  - H9N2 features, 403, 407
  - high-pathogenicity avian influenza viruses and genetic lineages associated with outbreaks, 428–435

- humoral immune response modeling to
    - hemagglutinin head and stem regions, 586–589
  - immune evasion, 58–59
  - membrane fusion
    - conformational changes at low pH, 45–46, 58
    - overview, 56–58
    - priming by precursor cleavage, 45, 57
  - neuraminidase interplay, 724–725
  - receptor binding
    - affinity and specificity, 40–45, 54–56
    - specificity by type
      - overview, 337
      - H1, 337
      - H2, 338–339
      - H3, 338–339
      - H4, 339
      - H5, 339
      - H6, 339–340
      - H7, 340
  - structure
    - comparison of structures from different techniques, 37
    - fusion subdomain F, 35, 37
    - group-specific features
      - comparison of groups, 37–40
      - rotation of R and E subdomains relative to F subdomain, 40
    - H1 hemagglutinin, 36
    - H3 hemagglutinin, 36
    - membrane anchor subdomain M, 37
    - overview, 33–35
    - vestigial esterase subdomain E, 35
  - swine influenza A virus phylogenetic lineages, 448–451
  - therapeutic targeting with antivirals, 688–690, 692–693
  - vaccine
    - antigens, 632–633
    - targeting, 64
  - HIV. *See* Human immunodeficiency virus
  - HOBIT, 558
  - Host factor identification, influenza virus
    - considerations in studies
      - controls, 158
      - host model system, 159
      - influenza virus strain, 158–159
      - proviral versus antiviral activity, 158
      - replication cycle stage, 158
      - type of host:virus interaction, 156, 158
    - importance of study, 155–156
    - prospects for study, 168–169
    - techniques for study
      - affinity purification mass spectrometry, 166–167
      - bimolecular fluorescent complementation, 165–166
      - CLIP-Seq, 167–168
      - CRISPR–Cas, 161–163
      - deep mutational scanning, 168
      - ectopic overexpression, 163
      - expression profiling, 163–164
      - gene correlation analysis, 163
      - knockout, 161–162
      - overview, 157, 159
      - RIP-Seq, 167–168
      - RNA interference, 159–161
      - single-nucleotide polymorphism analysis, 164
      - yeast two-hybrid screens, 164
  - Hsp90, 121–122
  - Human immunodeficiency virus (HIV), 250
- I**
- IAV. *See* Influenza A virus
  - IFITM, 601
  - IFITM3, 164
  - IFITM3*, 254–255, 324
  - IKK, 553
  - IL-1, 552–553
  - IL-6, 552
  - IL-8, 552
  - IL28B*, 254
  - Immune plasma, efficacy, 691–692
  - Immune response, influenza virus
    - B cells, 561–564
    - innate immunity
      - cGAS, 599
      - escape, 602
      - IFITM, 601
      - interferon response, 598–599
      - ISG15, 599–600
      - Mx1, 600
      - OASL, 600–601
      - overview, 10, 552, 595–597
      - pathogenesis, 552
      - PKR, 600
      - prospects for study, 604–605
      - RIG-I, 596, 598
      - STING, 599
      - Toll-like receptors, 596, 598
      - TRIMs, 601–602
      - virus regulation
        - M2, 604
        - NS1, 552–554, 602–603
        - PA-X, 554, 603–604

## Index

- Immune response, influenza virus (*Continued*)  
PB1-F2, 555, 604  
PB2, 556  
RNA polymerase, 603  
pediatric influenza, 268–270  
preexisting immunity  
  high levels in adults, 582–583  
  importance, 581–582  
  vaccination studies  
    boosting of response to different epitopes, 584–586  
  H5N1 prime and boost vaccination  
    antibody responses, 590  
  humoral immune response modeling to hemagglutinin head and stem regions, 586–589  
  memory recall responses after vaccination, 584–585  
  preexisting antibody titers and magnitude of response, 584  
  prospects for study, 590–592  
systems biological analysis of vaccination  
  immune response  
    goals, 614  
    historical perspective, 615–616  
    limitations and challenges, 623–624  
    proof-of-concept studies, 614–615  
  TLR5, 615–618  
vaccine development applications  
  adjuvant mechanism of action studies, 619–620  
  antibody response signatures and persistence, 620–622  
  antigen discovery, 622–623  
  protection mechanisms in challenge studies, 622  
  signatures of vaccine-induced immunogenicity and protection, 618–619
- T cells  
CD4 T cells  
  abundance and specificity of influenza-specific cells, 558–559  
  cytolytic cells, 558  
  follicular helper cells, 557–558  
  identification of cell subsets in protective immunity, 559–561  
  protective immunity, 556–557  
CD8 T cells  
  aging effects, 566–567  
  effector mechanisms, 566  
  overview, 564–565  
  protective immunity, 565  
  specificity, 566
- Immunization. *See* Vaccination  
IMP $\alpha$ , 117–118  
Inactivated influenza vaccine. *See* Vaccination  
Incomplete virus genome (IVG), transmission, 187–189
- Influenza A virus (IAV)  
bat viruses. *See* Bat influenza A viruses  
emerging HxNy viruses  
  hosts, 335–337  
  matching pattern of gene segments, 344–346  
  neuramidinase  
    drug resistance profile, 342–344  
    enzymatic activity, 340–341  
    inhibitor binding specificity, 341–342  
  overview, 331–332  
  pandemic viruses, 332–333–334  
  prospects for study, 346  
  receptor binding specificity of hemagglutinin type  
    H1, 337  
    H2, 338–339  
    H3, 338–339  
    H4, 339  
    H5, 339  
    H6, 339–340  
    H7, 340  
    overview, 337  
genome  
  packaging  
    models, 103  
    prospects for study, 107–108  
  ribonucleoprotein organization within virion, 103–105  
  RNA–RNA interactions, 105–107  
  segment-specific packaging, 102–103  
  structure, 2, 79–80, 100–102  
proteome  
  accessory proteome, 83–93  
  core proteome, 79–83  
  prospects for study, 93–94  
  swine viruses. *See* Swine influenza A viruses  
  synthetic virus. *See* Synthetic virology
- Innate immunity. *See* Immune response, influenza virus
- Interferon  
  influenza response, 598–599  
  systems biological analysis of vaccination  
    immune response, 615
- Intravenous immune globulin (IVIG), efficacy, 692  
IRF3, 553, 598  
IRF7, 598  
IRF9, 253

- ISG15, 599–600  
IVG. *See* Incomplete virus genome  
IVIG. *See* Intravenous immune globulin
- J**  
JNK, 144–146, 553
- L**  
Laninamivir  
  efficacy, 687–688  
  mechanism of action, 720  
  overview, 687  
  resistance, 688  
  safety, 688  
LASAG, 142  
LFA-1, 564  
LGALS1, 324  
LGP2, 598  
Live attenuated influenza vaccine. *See* Vaccination
- M**  
M1  
  influenza A virus function, 82  
  nuclear export, 129  
M2  
  influenza A virus function, 82, 114  
  innate immunity regulation, 604  
  vaccine antigens, 633  
M42, influenza A virus function, 88–89  
Malnutrition, severe influenza risks, 282–283  
Mass spectrometry (MS), affinity purification  
  mass spectrometry, 166–167  
MAVS, 556  
MCM, 121  
MCP-1, 552  
MDA5, 598  
MEDI8852  
  efficacy, 694  
  mechanism of action, 693  
Messenger RNA (mRNA), nuclear export, 120  
MHAA4549A  
  efficacy, 694  
  mechanism of action, 693  
Mini viral RNA (mvRNA), 8–10  
MIP-1 $\beta$ , 552  
mRNA. *See* Messenger RNA  
MS. *See* Mass spectrometry  
mvRNA. *See* Mini viral RNA  
Mx1, 600
- N**  
NA. *See* Neuraminidase  
NA43, influenza A virus function, 88  
NEP  
  influenza A virus function, 82  
  nuclear export, 129  
Neuraminidase (NA)  
  emerging HxNy viruses  
    drug resistance profile, 342–344  
    inhibitor binding specificity, 341–342  
  enzymatic activity, 340–341, 717–718  
  green fluorescent protein fusion, 179  
  hemagglutinin interplay, 724–725  
  influenza type distribution, 53  
  swine influenza A viruses genetic lineages, 444  
  therapeutic targeting, 685–688, 717–728  
  vaccine antigens, 633  
NF- $\kappa$ B. *See* Nuclear factor- $\kappa$ B  
1918 pandemic. *See* Spanish influenza pandemic  
Nitazoxanide (NTZ)  
  efficacy, 690  
  overview, 689–690  
  resistance, 690  
  safety, 690  
NLRP3, 553, 555, 596, 617  
NP  
  amino-terminally extended isoform, 88  
  influenza A virus function, 81  
  structure, 3  
  vaccine antigens, 634  
NS1  
  amino-terminally truncated isoforms, 89, 91  
  evolution, 554–555  
  influenza A virus function, 82  
  innate immunity regulation, 552–554, 602–603  
NS3, influenza A virus function, 91–92  
NTZ. *See* Nitazoxanide  
Nuclear factor- $\kappa$ B (NF- $\kappa$ B), 141–142, 553, 598  
Nuclear import. *See* Viral ribonucleoprotein  
NXF1, 120, 554  
NXT1, 120
- O**  
OAS. *See* Original antigenic sin  
OASL, 600–601  
Obesity, influenza infection risk, 251, 279–282  
Original antigenic sin (OAS)  
  aging and severe disease susceptibility, 287  
  costs and benefits, 537  
  immunological basis, 544–546  
  mechanisms, 536–537  
  misconceptions



## Index

- Original antigenic sin (OAS) (*Continued*)  
    constant feature of influenza virus immunity, 528, 533–535  
    inevitability, 535–536  
    limited to viruses within same subtype, 534  
    nonfunctional antibody generation, 534–535  
    restricted to antiviral immunity, 536–537  
overview, 527–528, 543–544, 561–552  
pediatric influenza effects, 544  
prospects for study, 537–538, 547–548  
recall antibody studies after infection  
    animal models, 531–532  
    humans, 529–530, 583–584  
vaccination effects in young children, 546–547
- Oseltamivir  
    antibiotic combination therapy, 695–696  
    derivatives, 720–721  
    H7N9 resistance, 375  
    mechanism of action, 114, 719–720  
    neuramidinase resistance, 342  
    resistance, 722
- P**
- p38 mitogen-activated protein kinase, influenza virus activation and therapeutic targeting, 144–146
- PA  
    IMP $\alpha$ -independent nuclear import, 118  
    influenza A virus function, 81
- PAFR, 282
- PA-N155, influenza A virus function, 86–87
- PA-N182, influenza A virus function, 86–87
- PA-X  
    influenza A virus function, 87–88  
    innate immunity regulation, 554–555, 603–604
- PB1  
    IMP $\alpha$ -independent nuclear import, 118  
    influenza A virus function, 81, 114
- PB1-F2  
    evolution, 555–556  
    influenza A virus function, 84, 86  
    innate immunity regulation, 555, 604
- PB1-N40, influenza A virus function, 86
- PB2  
    influenza A virus function, 81, 114  
    innate immunity regulations, 556  
    phylogeny, 202
- PB2-S1, influenza A virus function, 84
- Pediatric influenza  
    clinical presentation, 264–266  
    immune response, 268–270  
    original antigenic sin, 544  
    overview, 263–264  
    prospects for study, 270–272  
    transmission, 266–267  
    vaccination  
        mechanisms  
            inactivated vaccine, 270  
            live attenuated vaccine, 270  
        prevention, 267–268
- Peramivir, 720
- PI3K, influenza modulation, 146–149
- Pimodivir  
    efficacy, 682–683, 710  
    mechanism of action, 709–710  
    overview, 682, 709  
    resistance, 683, 710  
    safety, 683
- PIsK, 553
- PKR, 600
- PP7CP, 178
- Pregnancy, influenza susceptibility and severity, 251, 284–285
- Progesterone, 283
- Q**
- Quarantine, 308
- R**
- Rab11A, 130–131
- RAE1, 554
- Raf/MEK/ERK  
    classical MAPK cascade, 142–143  
    influenza virus activation and therapeutic targeting, 143–144  
    nuclear export role, 128–129
- RAF1, 121
- RAF2. *See* UAP56
- Rapamycin, efficacy against influenza, 697
- Reassortment. *See* Avian influenza viruses; Evolution, influenza viruses
- RED, 164
- Reverse genetics  
    historical perspective of influenza studies  
        alternative approaches, 224–225  
        bidirectional reverse genetics systems, 224  
        ribonucleoprotein complex isolation, 222  
        ribozyme generation of viral RNA 3' ends, 224  
    RNA polymerase I  
        features, 222–223  
        species specificity of promoter, 225–226  
        virus generation from cDNA, 223–224  
    non-influenza A viruses, 226  
    overview, 221  
    prospects, 226



- RIG-I, 10, 84, 114–115, 139–141, 148, 168, 553, 555, 596, 598
- rIPK, 146
- RIPLET, 598
- RIP-Seq, 167–168
- RNA polymerase I
- features in reverse genetics, 222–223
  - influenza virus generation from cDNA, 223–224
  - species specificity of promoter, 225–226
- RNA polymerase II, role in virus transcription, 118–120
- RNA polymerase, influenza virus (FluPol)
- conformational flexibility, 23–25
  - dimerization, 23–25
  - host factor interactions and adaptive mutations, 7–8
  - host-specific mutations in double domain, 21
  - innate immunity regulation, 603
  - mechanism of RNA synthesis
    - active site, 25–26
    - nucleotide addition cycle, 25–27
    - priming loop, 26, 28
  - overview, 15–17
  - promoter binding modes, 22–23
  - prospects for study, 29–30
  - replication, 6–7
  - RNA-binding sites, 4
  - structure
    - architecture, 3–4
    - domains
      - cap-binding domain, 17–19
      - endonuclease, 19–20
      - PA-C, 21–22
      - 627-NLS double domain, 20–21
    - overall structure, 16–17
    - therapeutic targeting, 680–684, 707–713
    - transcription, 4–6, 28–29
- RSK2, 144
- S**
- Seasonality, influenza, 302
- SELP, 622
- Sex differences, influenza susceptibility and severity, 250–251, 283–284
- Single-nucleotide polymorphism (SNP), analysis for influenza host factor identification, 164
- Sirolimus, efficacy against influenza, 697
- Small molecule–assisted shutoff (SMASH), 180–181
- Small viral RNA (svRNA), 8, 10
- SMASH. *See* Small molecule–assisted shutoff
- Smoking, influenza susceptibility and severity, 288
- SMU1, 164
- SNP. *See* Single-nucleotide polymorphism
- SOCS1, 280
- SOCS3, 280
- Spanish influenza pandemic
- global impact, 229–231
  - lessons learned, 238–239
  - origin, 231–233
  - pathogenicity, 233–238
  - recovery, 231
  - virus evolution, 204–205, 332
- STAT1, 145
- STAT4, 145
- STING, 599
- Susceptibility, influenza A virus infection
- immune correlates of protection and severity, 255–256
  - initial exposure, 246
  - occupational risks, 248
  - overview, 245–246
  - protecting high-risk populations, 289–290
  - severe disease susceptibility factors
    - age, 248–250, 285–287
    - bacterial coinfection, 252
    - chronic obstructive pulmonary disease, 252, 288
    - diabetes, 251, 288
    - genetic susceptibility
      - CD55*, 255
      - IFITM3*, 254–255
      - IL28B*, 254
      - IRF9*, 253
      - overview, 252–253
      - TLR3*, 253, 255
    - immunocompromised status, 250
    - microbiome disruption, 252
    - obesity, 251, 279–282
    - pregnancy, 251, 284–285
    - sex differences, 250–251, 283–284
    - vaccine history and preexisting immunity, 247–248
    - virus-intrinsic changes, 246–247
- svRNA. *See* Small viral RNA
- Swine influenza A viruses
- candidate vaccine virus development and assessment, 454–459
  - clinical aspects in pigs, 442, 445
  - current circulating diversity in swine, 447, 449–450, 452
  - evolution of sustained lineages
    - 1A, 445
    - 1B, 445–446
    - 1C, 446
    - H3, 446–447

## Index

- Swine influenza A viruses (*Continued*)  
  hemagglutinin phylogenetic lineages,  
    448–451  
  human risks, 452–454  
  neuraminidase genetic lineages, 444  
  overview, 441–442  
  phylogeny, 443  
  prospects for study, 458, 460
- Synthetic virology  
  applications, 182  
  circuit modules  
    browser history module, 179–180  
    genetic override module, 180  
    GPS module, 181  
    isolation, 178  
    RNA interference module, 181  
    tracking module, 178–179  
  influenza A virus circuitry, 176–178  
  overview, 175–176
- Systems vaccinology. *See* Vaccination
- T**
- Tamiflu. *See* Oseltamivir
- TBK-1, 140
- T cell, influenza immune response  
  CD4 T cells  
    abundance and specificity of influenza-  
      specific cells, 558–559  
    cytolytic cells, 558  
    follicular helper cells, 557–558  
    identification of cell subsets in protective  
      immunity, 559–561  
    protective immunity, 556–557  
  CD8 T cells  
    aging effects, 566–567  
    effector mechanisms, 566  
    overview, 564–565  
    protective immunity, 565  
    specificity, 566  
  efficacy, 694–695  
  mechanism of action, 693
- TCN-032
- Test-negative design (TND), 649–650, 664
- Testosterone, 283
- TLR3, 598
- TLR3*, 253, 255
- TLR4, 145
- TLR5, systems biological analysis of vaccination  
  immune response, 615–618
- TLR7, 598
- TLR8, 598
- TMPRSS2*, 324
- TND. *See* Test-negative design
- TNPO1, 115
- TRAIL, 142
- Transcription  
  RNA polymerase, influenza virus,  
    4–6, 28–29  
  RNA polymerase II role in virus transcription,  
    118–120
- Transmission  
  animal models  
    age effects, 194–195  
    immune status studies, 194  
    microbiome studies, 194–195  
    overview, 193  
    route of transmission, 193–194  
  bottlenecks  
    influenza diversity, 186–187  
    quantification, 190–193  
  cross-species transmission and evolution,  
    205–207  
  defective and incomplete virus particles,  
    187–189  
  emerging influenza viruses, 189–190  
  equine influenza viruses, 471–472  
  ferrets and influenza virus, 515–517  
  H7N9 in China, 374–375  
  H9N2, 396–397, 403  
  modeling, 301–302  
  overview, 185–186  
  pediatric influenza, 266–267  
  prospects for study, 195
- TRIM14, 602
- TRIM22, 602
- TRIM25, 555, 598
- TRIM28, 145
- TRIM32, 602
- TRIM56, 601
- Tuberculosis, influenza susceptibility  
  and severity, 289
- U**
- UAP56, 121–123
- Umifenovir  
  efficacy, 688–689  
  overview, 688  
  resistance, 689  
  safety, 689
- Vaccination  
  antigen targets, 632–634  
  biological challenges, 631–632  
  effectiveness and efficacy  
  end points, 648–649

- host factors affecting
    - imprinting and cohort effects, 653
    - repeated vaccinations, 651–653
  - inactivated influenza vaccines
    - adjuvanted vaccine, 654
    - cell culture-based vaccine, 655
    - high-dose vaccine, 654–655
    - recombinant vaccine, 655
  - observational studies, 648
  - overview, 647–649
  - prospects for study, 655–656
  - randomized controlled trials, 648
  - relative effectiveness study
    - challenges, 655
  - test-negative design, 649–650
  - vaccine effectiveness by influenza type
    - H1N1, 650
    - H3N2, 650–651
    - type B, 651
  - virus factors affecting
    - egg-induced mutations, 651
    - strain, 651
    - waning, 653–654
  - equine influenza viruses, 475–476
  - H5N1 in Egypt, 360
  - H7N9 in China, 376–377
  - H9N2, 407
  - hemagglutinin targeting, 64
  - historical perspective, 629–631
  - infection susceptibility impact, 247–248
  - live attenuated influenza vaccine
    - clinical experience
      - pandemic of 2009, 664
      - randomized studies, 665
      - U.S. influenza VE network, 664–665
    - historical perspective, 662–664
    - overview, 661–662
    - pandemic vaccines, 670–671
    - prospects, 671–672
    - protection correlates, 669–670
    - Russian backbone vaccine, 668–669
    - vaccine effectiveness against H1N1, 665–668
  - monitoring, 306–307
  - next-generation vaccines
    - high-performance seasonal vaccines, 634
    - pandemic
      - preparedness, 637
      - response, 637–638
    - prospects, 639–640
    - supraseasonal vaccines, 634–637
    - universal vaccines, 638–639
  - original antigenic sin effects in young children, 546–547
  - pediatric influenza
    - mechanisms
      - inactivated vaccine, 270
      - live attenuated vaccine, 270
    - prevention, 267–268
  - preexisting immunity studies
    - boosting of response to different epitopes, 584–586
    - H5N1 prime and boost vaccination antibody responses, 590
    - humoral immune response modeling to hemagglutinin head and stem regions, 586–589
    - memory recall responses after vaccination, 584–585
    - preexisting antibody titers and magnitude of response, 584
    - prospects for study, 590–592
  - swine influenza A virus candidate vaccine
    - virus development and assessment, 454–459
  - systems biological analysis of immune response
    - goals, 614
    - historical perspective, 615–616
    - limitations and challenges, 623–624
    - proof-of-concept studies, 614–615
    - TLR5, 615–618
    - vaccine development applications
      - adjuvant mechanism of action studies, 619–620
      - antibody response signatures and persistence, 620–622
      - antigen discovery, 622–623
      - protection mechanisms in challenge studies, 622
      - signatures of vaccine-induced immunogenicity and protection, 618–619
- V**
- VDAC1, 555
  - Viral ribonucleoprotein (vRNP)
    - architecture, 3, 100–102
    - nuclear export
      - CLUH role, 130
      - CRM1 role, 129–130
    - overview, 127
    - plasma membrane transport, 130–131
    - Raf/MEK/ERK signaling, 128–129
    - nuclear import

## Index

- Viral ribonucleoprotein (vRNP) (*Continued*)
- classical pathway, 116–117
  - IMP $\alpha$ -independent nuclear import, 118
  - noncanonical roles of  $\alpha$ -importins, 117–118
  - overview, 115
  - precursor steps, 115–116
  - organization within virion, 103–105
- VIS410
- efficacy, 695
  - mechanism of action, 693
- vRNP. *See* Viral ribonucleoprotein
- Y**
- Yeast two-hybrid screens, 164
- Z**
- Zanamivir
- efficacy, 686
  - overview, 685–686, 719
  - resistance, 687, 722
  - safety, 686–687